Figure 3
From: Identification of RSPO2 Fusion Mutations and Target Therapy Using a Porcupine Inhibitor
The elevation of LGR5 + cell proliferation and migration by RSPO2. (a) RSPO2 enhances the WNT pathway activity in dosing dependent manner, the EC50 = 8.65 ng/mL. (b,c) Cell proliferation curves of HEK293 and LoVo cells activated by culture medium containing 10 ng/mL RSPO proteins. (d,e) HEK293 and LoVo Foci formation assay, Left: control group, Right: experimental group with 10 ng/mL RSPO2 added in cell culture medium. (f,g) HEK293 and LoVo transwell migration assay, Left: vehicle group, Right: experimental group containing 10 ng/mL RSPO2 in cell culture medium. *p < 0.05, **p < 0.01, ***p < 0.001.
